局部藥物 CDMO 市場 - 按產品類型、治療領域、服務類型、最終用戶、全球預測

Topical Drugs CDMO Market - By Product Type, Therapeutic Area, Service Type, End-user, Global Forecast

出版日期: 2024年04月22日 | 出版商:

Global Market Insights Inc. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在消費者對非處方產品偏好增強的推動下，2024 年至 2032 年全球外用藥物 CDMO 市場複合年成長率將超過 12.1%。隨著消費者尋求方便且具成本效益的醫療保健解決方案，對霜劑和藥膏等非處方藥局部治療的需求正在上升。這些產品在零售和網路藥局的供應量不斷增加，也支持了這一趨勢。

隨著製藥公司外包非處方藥產品的開發和製造以滿足需求，CDMO 受益於此轉變。因此，對自我保健和輕鬆獲得非處方藥的關注繼續推動外用藥物的 CDMO 市場。最近的一項雜貨店Doppio 調查顯示，70% 的消費者嘗試過自有品牌產品，其中50% 的消費者計劃在2024 年繼續購買這些產品。有品牌。

外用藥物 CDMO 產業根據產品類型、治療領域、服務類型、最終用戶和地區進行分類。

外用藥物CDMO 市場的液體製劑部分將在2024 年至2032 年間經歷顯著的複合年成長率。應用的首選。此細分市場的成長得益於配方技術的創新和消費者對液體保養品的偏好增加。製藥公司擴大將液體外用藥物的開發和製造外包給 CDMO，以利用他們的配方開發和監管合規專業知識，推動這一專業領域的市場擴張。

由於全球慢性疼痛的盛行率不斷增加，到 2032 年，疼痛管理領域將獲得相當大的外用藥物 CDMO 市場佔有率。外用製劑可提供非侵入性和局部疼痛緩解，是尋求口服藥物替代品的患者的首選。這一趨勢得到了經皮給藥技術進步的支持，並提高了局部疼痛治療的功效和安全性。製藥公司正在利用 CDMO 在製劑開發和製造方面的專業能力，以滿足對創新局部疼痛管理解決方案不斷成長的需求，並推動這一專業細分市場的擴張。

亞太地區外用藥物 CDMO 市場規模在預測期間內將呈現顯著的複合年成長率。醫療保健支出的增加、慢性皮膚病患病率的增加以及藥品市場的擴張正在推動成長。亞太地區人口眾多、醫療基礎設施改善以及監管改革為 CDMO 創造了機會。公司擴大外包外用藥物的開發和製造，以利用該地區熟練的勞動力和具有成本效益的製造能力。隨著亞太地區繼續成為醫藥創新和生產中心，外用藥物專業 CDMO 服務的需求預計將大幅成長。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Ascendia Pharmaceuticals
Bora Pharmaceutical CDMO
Cambrex Corporation
Contract Pharmaceuticals Limited
DPT Laboratories, Ltd.
The Lubrizol Corporation
MedPharm Ltd
PCI Pharma Services
Pierre Fabre Group
Piramal Pharma Solutions

」

簡介目錄

Product Code: 9137

Global Topical Drugs CDMO Market will witness over 12.1% CAGR from 2024 to 2032, spurred by the strengthening consumer preference for over-the-counter products. As consumers seek convenient and cost-effective healthcare solutions, the demand for OTC topical treatments, such as creams and ointments, is rising. This trend is supported by the increasing availability of these products in retail and online pharmacies.

CDMOs benefit from this shift as pharmaceutical companies outsource the development and manufacturing of OTC products to meet demand. Consequently, the focus on self-care and easy access to OTC medications continue to bolster the CDMO market for topical drugs. A recent grocery doppio survey reveals that 70% of consumers have tried private-label products, with 50% planning to continue purchasing them into 2024. This trend indicates a growing shift towards private labels in the retail market.

The topical drugs CDMO industry is classified based on product type, therapeutic area, service type, end-user, and region.

The liquid formulation segment in the topical drugs CDMO market will experience a notable CAGR between 2024 and 2032. Liquid formulations offer advantages such as ease of application, faster absorption, and potential for precise dosing, making them preferred for various dermatological and cosmetic applications. This segment's growth is ushered by innovations in formulation techniques and increased consumer preference for liquid-based skincare products. Pharmaceutical companies are increasingly outsourcing liquid topical drug development and manufacturing to CDMOs to capitalize on their formulation development and regulatory compliance expertise, fueling market expansion in this specialized area.

The pain management segment will garner considerable topical drugs CDMO market share by 2032 because of the increasing prevalence of chronic pain conditions globally. Topical formulations offer non-invasive and localized pain relief, preferred by patients seeking alternatives to oral medications. This trend is supported by advancements in transdermal delivery technologies, enhancing the efficacy and safety profiles of topical pain treatments. Pharmaceutical companies are leveraging CDMOs' specialized capabilities in formulation development and manufacturing to meet the rising demand for innovative topical pain management solutions, driving expansion in this specialized market segment.

Asia Pacific topical drugs CDMO market size will exhibit a significant CAGR during the forecast period. Rising healthcare expenditure, increasing prevalence of chronic skin conditions, and expanding pharmaceutical markets are driving growth. Asia Pacific's large population and improved healthcare infrastructure and regulatory reforms foster opportunities for CDMOs. Companies are increasingly outsourcing topical drug development and manufacturing to capitalize on the region's skilled workforce and cost-effective manufacturing capabilities. As Asia Pacific continues to emerge as a hub for pharmaceutical innovation and production, the demand for specialized CDMO services in topical drugs is expected to rise significantly.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing demand for topical medications
  - 3.2.1.2 Growing adoption of outsourcing of manufacturing activities
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Challenges in quality control
  - 3.2.2.2 High capital investment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Semi-solid formulations
- 5.2.1 Creams
- 5.2.2 Ointments
- 5.2.3 Gels
- 5.2.4 Other semi-solid formulations
5.3 Liquid formulation
5.4 Trans dermal products
5.5 Solid formulations

Chapter 6 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Dermatology
6.3 Pain management
6.4 Wound care
6.5 Ophthalmology
6.6 Other therapeutic areas

Chapter 7 Market Estimates and Forecast, By Service Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Contract manufacturing
7.3 Contract development

Chapter 8 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Pharmaceutical companies
8.3 Biotechnology companies
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa